<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02546297</url>
  </required_header>
  <id_info>
    <org_study_id>20150717</org_study_id>
    <nct_id>NCT02546297</nct_id>
  </id_info>
  <brief_title>Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis</brief_title>
  <official_title>The Comparisons of the Efficacy and Safety of Inhaled LAMA or LAMA+LABA or ICS+LABA for Patients in COPD C Group With Bronchiectasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Pulmonary Hospital, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Pulmonary Hospital, Shanghai, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine which treatment is more effective and safer for the
      patients in COPD C group with bronchiectasis.The research results will help guide physicians
      to select appropriate individualized treatment and hopefully provide some evidence-based
      medicine proofs for revising guide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The diagnosis and treatment of COPD and bronchiectasis together seems to be more complicated
      than the diagnosis and treatment of either condition alone. According to the GOLD，there are
      three treatments for patients with COPD in group C: ICS combined with LABA or LAMA alone or
      LABA combined with LAMA. However, it has not yet been demonstrated about which method is more
      effective for the patients with COPD in group C and bronchiectasis.

      This study is designed as a prospective, randomized, case-control trial. Patients are divided
      into three groups, one group inhaled with ICS and LABA (Symbicort), the second group inhaled
      with LAMA (Tiotropium Bromide) and the third group inhaled with LAMA(Tiotropium Bromide) and
      (Symbicort).The course of treatment is 12 months.

      The investigators will also assess other relevant outcomes, including the quality of life
      (QOL) score, pulmonary function test and the incidence of adverse event.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 15, 2017</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute exacerbation</measure>
    <time_frame>12 months</time_frame>
    <description>The times of acute exacerbation during the trial.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>All of the adverse events occurred in the processing of the trial,especially the prevalence of pneumonia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1</measure>
    <time_frame>12 months</time_frame>
    <description>Forced Expiratory Volume in one second</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC</measure>
    <time_frame>12 months</time_frame>
    <description>Forced Vital Capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1/FVC</measure>
    <time_frame>12 months</time_frame>
    <description>Pulmonary function test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SGRQ</measure>
    <time_frame>12 months</time_frame>
    <description>St. George's Respiratory Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LCQ</measure>
    <time_frame>12 months</time_frame>
    <description>The Leicester Cough Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAT</measure>
    <time_frame>12 months</time_frame>
    <description>COPD Assessment Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mMRC</measure>
    <time_frame>12 months</time_frame>
    <description>Modified Medical Research Council Dyspnea Scale</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>COPD</condition>
  <condition>Bronchiectasis</condition>
  <arm_group>
    <arm_group_label>ICS/LABA Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Symbicort，Inhalation，Individualized medication，12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LAMA Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tiotropium Bromide，Inhalation,Individualized medication，12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LAMA+LABA Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tiotropium Bromide, Symbicort, Inhalation, Individualized medication, 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symbicort</intervention_name>
    <description>drug are used for 12 months</description>
    <arm_group_label>ICS/LABA Group</arm_group_label>
    <arm_group_label>LAMA+LABA Group</arm_group_label>
    <other_name>Budesonide/Formoterol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spiriva</intervention_name>
    <description>drug are used for 12 months</description>
    <arm_group_label>LAMA Group</arm_group_label>
    <arm_group_label>LAMA+LABA Group</arm_group_label>
    <other_name>Tiotropium Bromide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients are suitable for inclusion in the study when they are 18 years or older
             diagnosed with COPD C group and bronchiectasis.

        Exclusion Criteria:

          -  active tuberculosis

          -  severe respiratory disease (such as Lung cancer, ARDS, pulmonary encephalopathy,
             respiratory failure)

          -  uncontrollable diabetes

          -  hypersensitivity to any components of ICS/LABA or LAMA.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin-Fu Xu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Pulmonary Hospital , Tongji University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Oba Y, Lone NA. Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2014 May 12;9:469-79. doi: 10.2147/COPD.S48492. eCollection 2014. Review.</citation>
    <PMID>24872685</PMID>
  </results_reference>
  <results_reference>
    <citation>Kew KM, Dias S, Cates CJ. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database Syst Rev. 2014 Mar 26;(3):CD010844. doi: 10.1002/14651858.CD010844.pub2. Review.</citation>
    <PMID>24671923</PMID>
  </results_reference>
  <results_reference>
    <citation>Manoharan A, Short PM, Anderson WJ, Lipworth BJ. Impact of long-acting bronchodilators and exposure to inhaled corticosteroids on mortality in COPD: a real-life retrospective cohort study. Lung. 2014 Oct;192(5):649-52. doi: 10.1007/s00408-014-9611-8. Epub 2014 Jun 22.</citation>
    <PMID>24952426</PMID>
  </results_reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 22, 2015</study_first_submitted>
  <study_first_submitted_qc>September 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2015</study_first_posted>
  <last_update_submitted>July 29, 2019</last_update_submitted>
  <last_update_submitted_qc>July 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Pulmonary Hospital, Shanghai, China</investigator_affiliation>
    <investigator_full_name>Jin-Fu Xu</investigator_full_name>
    <investigator_title>Department of Respiratory Medicine</investigator_title>
  </responsible_party>
  <keyword>LAMA,ICS+LABA,LAMA+LABA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

